急性骨髓性白血病治疗市场（依治疗类型、作用机制、治疗线、最终使用者、给药途径及病患年龄划分）－2025-2032年全球预测

预计到 2032 年，急性骨髓性白血病治疗市场规模将成长 26.1 亿美元，复合年增长率为 12.46%。

关键市场统计数据
基准年 2024	10.2亿美元
预计年份：2025年	11.4亿美元
预测年份 2032	26.1亿美元
复合年增长率 (%)	12.46%

本文简明扼要地概述了急性骨髓性白血病治疗的发展历程，重点介绍了其临床复杂性、精准治疗方法和商业性重要性。

急性骨髓性白血病(AML) 是临床上最复杂的骨髓恶性肿瘤之一，其特征是遗传因素异质性、患者群体多样化以及治疗模式不断演变。过去十年，治疗方法已从广谱细胞毒性方案转向精准标靶治疗和免疫肿瘤治疗方法。这一转变得益于对分子机制的深入理解、诊断分层技术的改进以及先进生物製药和细胞疗法的成熟。因此，研究、临床和商业领域的相关人员面临着一个快速变化的环境，需要采取相应的适应性策略。

临床医生目前需要在既定的治疗方案推广和维持框架与不断扩充的标靶抑制剂、表观遗传调变器和细胞疗法等治疗手段之间寻求平衡。同时，支付方和医疗服务体係也正在调整报销方式，以兼顾高成本的一次性治疗和长期疗效。这些动态变化既为製造商、合约研究与受託製造厂商以及供应链合作伙伴带来了机会，也带来了营运上的复杂性。因此，对于在急性髓性白血病（AML）治疗领域做出投资、合作和产品上市决策的领导者而言，清晰且切实地整合临床趋势、监管变化和商业性需求至关重要。

本书权威地探讨了科学、监管和商业性力量的融合如何重塑急性骨髓性白血病药物的研发和上市。

急性骨髓性白血病）的治疗格局正在经历一场变革，这主要得益于科学进步、监管环境的演变以及商业性创新三者的共同推动。精准医疗已从概念阶段迈向临床实践阶段，基因组分析和微量残存疾病检测等技术使得患者筛选更加精准，治疗策略也更具适应性。同时，生物製剂平台（包括抗体药物复合体和融合蛋白）的日益成熟，拓展了治疗适应症，并实现了靶向细胞毒性药物递送，进一步促进了这一转变。此外，细胞疗法的研发和规模化生产带来了持久疗效的可能，同时也对生产和物流提出了独特的要求。

同时，监管框架也在不断发展，以适应新型治疗方法和替代终点。支付方正积极回应，推出基于价值的合约试点计画和基于结果的报销模式，将初始成本与疗效的持久性挂钩。产业联盟蓬勃发展，汇聚药物研发、转化科学和商业性准入等方面的专业知识，改变了传统的竞争动态。因此，成功越来越依赖整合临床开发、供应链准备和支付方参与的整合策略，而非以产品为中心的独立计画。

对2025年贸易政策累积影响对AML药物供应链、生产投资选择与取得途径的清晰分析

2025年高关税制度的实施和贸易政策的转变将对急性髓系白血病（AML）治疗价值链产生显着的连锁反应，其累积影响主要体现在供应链韧性、生产策略以及患者成本动态等。生技药品和细胞疗法生产中使用的依赖进口的组件，包括专用试剂、一次性系统和关键设备，其采购模式已发生转变，促使製造商和合约合作伙伴重新评估采购区域和库存缓衝。为此，一些相关人员加快了近岸外包的步伐，并使其供应商网路多元化，以降低关税相关干扰带来的风险。

除了采购之外，关税也影响了新生产能力的资本投资决策，尤其是那些需要专用无尘室设施和低温运输基础设施的复杂配方产品。计划新建工厂的公司需要在不断上涨的设备和零件进口关税与区域供应安全的长期战略需求之间权衡利弊。此外，进口原料到岸成本的上升也给价格谈判和分销协议带来了压力，进而影响了医院和专科诊所的癌症药物预算。这些压力凸显了製造商和支付方之间进行透明成本分析和建立协作合约机制的必要性。

最后，关税政策日益强调监管和海关协调，以减少行政延误，从而降低贸易措施带来的经济影响。相关人员积极与政策制定者和产业协会合作，以明确生物製药和先进治疗成分的关税分类，并在国家卫生优先事项需要加快取得途径时，争取豁免。因此，那些积极调整筹资策略、加强区域製造地并与政策制定者进行建设性沟通的公司，已在不断变化的贸易环境中占据有利地位，能够维持供应的连续性并保障患者的用药需求。

全面的細項分析揭示了治疗方式、机制、治疗环境、给药途径和患者人口统计特征如何决定临床和商业策略。

细分洞察揭示了不同疗法类型、作用机制、治疗线、最终用户、给药途径和患者族群所带来的差异化商业机会和营运需求。治疗方法方案多种多样，包括生物製药（如抗体药物复合体、融合蛋白和单株抗体）、细胞疗法（如CAR-T疗法和干细胞移植）、基因疗法、BCL-2抑制剂、DNA甲基转移酶抑制剂和蛋白酪氨酸激酶抑制剂，以及小分子药物（可细分为标靶FLT3和KIT的药物）。这种治疗模式的细分对临床试验设计、生产复杂性和核准后证据的产生有显着影响。

基于机制的细分方法揭示了BCL-2抑制、DNA甲基转移酶抑制剂介导的表观遗传修饰、组蛋白去乙酰化酶修饰、免疫调节剂以及蛋白酪氨酸激酶抑制剂如何对联合治疗策略和抗药性管理产生不同的影响。就治疗线而言，第一线治疗方案优先考虑新诊断族群的持久性和耐受性，二线治疗方案强调挽救性疗效和安全性，而三线及后续治疗方案则着重于克服获得性抗药性和控制累积毒性。终端用户细分方法强调，医院药房必须协调住院患者的给药和复杂生技药品的低温运输储存，零售药房负责门诊口服药物的配药，而专科诊所则在高度控制的条件下提供先进的细胞疗法。

按给药途径细分，可区分静脉输液疗法（需要输液基础设施和监测）和口服药物（可在家中服用，但需要依从性支持）；皮下注射可减轻输液负担，但需要患者教育和给药培训。依患者年龄细分，可知成人患者占治疗决策的大多数，老年患者通常需要调整剂量和合併症管理，而儿童患者则需要考虑安全性和发育因素。整合这些细分讯息，有助于相关人员确定临床开发路径的优先顺序，协调生产和分销投资，并根据不同的给药方式、机制、护理环境和患者群体，制定差异化的市场开发方法。

详细的区域展望，重点介绍主要全球市场在市场驱动因素、监管预期和营运重点方面的差异

区域洞察凸显了美洲、中东和非洲以及亚太地区在应用驱动因素、监管预期和营运重点方面的差异，这些差异对临床开发和商业化都有独特的影响。在美洲，分散的支付方结构和先进的报销机制与强大的临床试验网络和成熟的肿瘤中心并存，这使得证据生成和价值论证对于高端产品的获取和应用至关重要。相反，在中东和非洲，集中化的法律规范和不同的报销门槛凸显了卫生技术评估和区域定价策略的重要性。

亚太地区拥有庞大的患者群体、不断提升的诊断能力和日益扩大的生产能力，因此具备加速推广应用的潜力。然而，该地区管理体制的多样性和成本敏感性也使其需要製定区域性的临床开发计划和灵活的商业模式。在任何地区，低温运输的稳定性、本地生产伙伴关係以及快速的监管反应等物流因素都会对产品上市顺序和市场准入时间产生重大影响。因此，采取兼顾全球集中协调和本地执行能力的区域性策略，将有助于最大限度地扩大患者覆盖率并实现商业性的永续性。

透过将科学差异化与生产规模和以支付方为中心的证据产生相结合，使公司的策略行动和竞争策略保持一致。

急性髓系白血病（AML）治疗生态系统中的主要企业正在寻求将深厚的科学差异化与切实可行的商业计划相结合的策略。大型製药企业正利用其成熟的商业基础设施和全球开发经验，加速后期专案的推进，并儘早与支付方展开对话。中型生物技术公司和细胞疗法专家则专注于敏捷创新，瞄准分子定义的亚群，并寻求策略联盟以弥补生产和全球市场准入方面的能力缺口。越来越多的公司正在进行合作，将专有平台与互补资产结合，以降低临床试验风险并扩大复杂生产流程的规模。

为了加快患者用药速度，生产合作伙伴和委外研发机构正在投资一次性技术、封闭式细胞处理系统以及分散式填充和包装解决方案，从而拓展先进疗法的研发能力。同时，市场参与企业正着重采用差异化的临床试验设计，结合生物标记主导的入组和自适应终点，为监管机构和支付方提供强有力的证据。商业性策略也反映出向价值定价、结果追踪和综合服务（包括诊断和患者支持）的转变。那些能够将临床创新与稳健的供应链和符合支付方需求的证据产生相结合的公司，将在将科学成果转化为永续的患者用药方面保持竞争优势。

为协调临床开发、生产韧性和支付方参与，以加速药物可及性和商业性成功，提出切实可行的策略建议。

产业领导者应采取一系列实际有效、影响深远的行动，使研发重点与商业化实际情况相符，同时保障供应的连续性和与支付方的关係。首先，优先考虑以生物标记主导的临床路径和适应性试验设计，以降低后期研发风险，并提高核准和报销的可能性。其次，加速供应商网路多元化，考虑区域性生产投资以减少贸易中断的影响，并加速产品惠及病患的速度。第三，在研发规划早期阶段就纳入健康经济学和结果研究，以产生基于价值的合约和差异化定价所需的真实世界证据。

此外，我们将促进跨领域伙伴关係，将研发平台与生产和分销专长结合，以加速复杂疗法的规模化生产。我们将投资于远端患者监护和依从性支持的数位化工具，特别是针对口服和皮下注射疗法，以展示其在真实世界中的疗效，并支持基于结果的合约。最后，我们将积极与政策制定者和相关人员沟通，明确一次性治疗和高成本治疗的报销途径，并倡导监管协调，以减少及时获得治疗的行政障碍。这些措施将共同增强韧性，加速治疗普及，并使商业性预期与临床实际情况相符。

采用透明严谨的混合方法研究途径，结合专家访谈、文献回顾和证据三角验证，确保获得可靠的研究结果。

调查方法采用多层次、可重复的方法，结合定性和定量技术，以确保研究结果的稳健性和三角验证。主要研究包括对临床医生、临床实验、支付方和行业高管进行结构化访谈，以了解临床实践、报销动态和营运限制等方面的基层观点。专家咨询有助于对供应链中断和监管变化进行情境分析，而临床实验的研究综述则提供了有关真实世界治疗模式和仿单标示外用药的背景资讯。

二次研究包括对同行评审文献、临床试验註册库、监管指南和公司披露资讯进行全面审查，以建立机制特异性疗效和安全性特征的依证。商业性资讯来自产品附加檔、会议论文集和公开竞标，并评估了不同医疗机构的可近性。资料综合采用定性编码、比较框架分析以及与多个独立资讯来源的交叉检验，以减少偏差并提高可靠性。透过记录资料来源并对关键假设进行敏感度检验和专家检验，确保了调查方法的透明度。

这是一份简明扼要、综合全面的总结，重点阐述了为实现对患者的持续影响，临床、生产和商业策略之间需要如何协调一致。

总之，急性髓系白血病（AML）治疗领域呈现出以下特点：科学创新加速、监管环境和支付方预期不断变化，以及日益复杂的运作模式重塑了患者获得治疗的途径。成功的研发需要整合策略，将分子标靶的临床开发与稳健的生产製造、符合支付方需求的证据生成以及本地化的商业化计划相结合。积极应对供应链脆弱性、采用适应性临床设计并儘早与支付方接洽的利益相关人员，将更有能力将治疗方法进展转化为永续的临床和商业性成果。

精准诊断、先进生技药品和细胞疗法的未来融合，若能促使产业相关人员在科学、监管和商业领域通力合作，将显着改善病患的治疗效果。透过将能力建构投资与策略伙伴关係结合，并在整个研发过程中融入卫生经济学理念，企业可以克服复杂性，为病患和医疗保健系统创造实际价值。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

• FLT3抑制剂在急性髓性白血病（AML）一线治疗和復发/难治性患者治疗中的出现，以及生存率的提高，都促进了AML患者的康復。
• 扩大MLL基因重排和NPM1基因突变的menin抑制剂治疗急性骨髓性白血病的临床试验
• 针对 CD33 和 CD123 抗原的双特异性 T 细胞衔接器的开发推动了急性髓性白血病 (AML) 免疫疗法的创新。
• 利用次世代定序，结合微小残留病灶（MRD）所指导的治疗调整，实现急性髓性白血病（AML）治疗策略的个人化。
• 一种口服BCL-2抑制剂疗法核准并上市，为老年急性髓系白血病（AML）患者提供了一种无需化疗的选择。
• 研究针对急性髓性白血病特异性抗原的CAR-T细胞疗法，以克服復发病例的治疗抗药性
• 采用标靶表观遗传调变器（例如 IDH1/2 抑制剂）将重塑急性髓系白血病 (AML) 的治疗模式。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章急性骨髓性白血病药物市场（依治疗类型划分）

• 生物製药
  • 抗体药物复合体
  • 融合蛋白
  • 单株抗体
• 细胞疗法
  • CAR-T细胞疗法
  • 干细胞移植
• 基因治疗
• 小分子
  • BCL-2抑制剂
  • DNA甲基转移酵素酶抑制剂
  • 蛋白酪氨酸激酶抑制剂
    • FLT3抑制剂
    • KIT抑制剂

第九章急性骨髓性白血病药物市场依作用机转划分

• BCL-2抑制剂
• DNA甲基转移酵素酶抑制剂
• HDAC抑制剂
• 免疫调节药物
• 蛋白酪氨酸激酶抑制剂

第十章急性骨髓性白血病药物市场治疗方案

• 第一排
• 第二行
• 三线及以后

第十一章急性骨髓性白血病药物市场（按最终用户划分）

• 医院药房
• 零售药房
• 专科诊所

第十二章急性骨髓性白血病药物市场依给药途径划分

• 静脉
• 口服
• 皮下

第十三章 依患者年龄分類的急性骨髓性白血病药物市场

• 成人版
• 老年人
• 孩子们

第十四章急性骨髓性白血病药物市场（按地区划分）

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十五章急性骨髓性白血病药物市场（依组别划分）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第十六章 各国急性骨髓性白血病药物市场

• 美国
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十七章 竞争格局

• 2024年市占率分析
• FPNV定位矩阵，2024
• 竞争分析
  • AbbVie Inc.
  • F. Hoffmann-La Roche Ltd
  • Pfizer Inc.
  • Jazz Pharmaceuticals plc
  • Novartis AG
  • Bristol Myers Squibb Company
  • Astellas Pharma Inc.
  • Agios Pharmaceuticals, Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Daiichi Sankyo Company, Limited

The Acute Myeloid Leukemia Therapeutics Market is projected to grow by USD 2.61 billion at a CAGR of 12.46% by 2032.

KEY MARKET STATISTICS
Base Year [2024]	USD 1.02 billion
Estimated Year [2025]	USD 1.14 billion
Forecast Year [2032]	USD 2.61 billion
CAGR (%)	12.46%

A concise foundational overview of acute myeloid leukemia therapeutic evolution highlighting clinical complexity, precision approaches, and commercial imperatives

Acute myeloid leukemia (AML) remains one of the most clinically complex hematologic malignancies, characterized by heterogeneous genetic drivers, variable patient demographics, and evolving therapeutic paradigms. Over the past decade, the therapeutic landscape has shifted from broadly cytotoxic regimens toward precision-targeted approaches and immuno-oncology modalities. This transition has been driven by deeper molecular understanding, improved diagnostic stratification, and maturation of advanced biologics and cellular therapies. Consequently, stakeholders across research, clinical practice, and commercial functions face a rapidly changing environment that demands adaptive strategies.

Clinicians now balance established induction-maintenance frameworks with an expanding armamentarium of targeted inhibitors, epigenetic modulators, and cell-based interventions. At the same time, payers and provider systems are adapting reimbursement approaches to account for high-cost one-time therapies and long-term outcomes. These dynamics create both opportunities and operational complexities for manufacturers, contract development and manufacturing organizations, and supply-chain partners. Therefore, a clear, actionable synthesis of clinical trends, regulatory shifts, and commercial imperatives is essential for leaders making investment, alliance, and launch decisions in the AML therapeutics arena.

An authoritative examination of the converging scientific, regulatory, and commercial forces reshaping acute myeloid leukemia therapy development and access

The AML therapeutic landscape is experiencing transformative shifts driven by converging scientific advances, regulatory evolution, and commercial innovation. Precision medicine has moved from concept to clinical routine as genomic profiling and minimal residual disease assays enable more refined patient selection and adaptive treatment strategies. This shift is complemented by the maturation of biologic platforms, including antibody drug conjugates and fusion proteins, that extend the therapeutic index and permit targeted cytotoxic delivery. Simultaneously, the development and scaling of cell therapies have introduced durable response potential while imposing unique manufacturing and logistics requirements.

Concurrently, regulatory pathways are evolving to accommodate novel modalities and surrogate endpoints, which accelerates time-to-access but also raises evidentiary demands for long-term safety and real-world effectiveness. Payers are responding with value-based contracting pilots and outcomes-based reimbursement models that link upfront cost to durability of response. Industry partnerships are proliferating to pool expertise across discovery, translational science, and commercial access, altering traditional competitive dynamics. As a result, success increasingly depends on integrated strategies that align clinical development with supply-chain readiness and payer engagement, rather than isolated product-centered plans.

A clear analysis of cumulative trade policy impacts on AML therapeutic supply chains, manufacturing investment choices, and access considerations in 2025

The introduction of elevated tariff regimes and trade policy shifts in 2025 created tangible ripple effects across the AML therapeutics value chain, with cumulative impacts centering on supply-chain resilience, manufacturing strategy, and cost-to-patient dynamics. Import-dependent components used in biologics and cell therapy manufacturing, including specialized reagents, single-use systems, and critical equipment, saw altered procurement profiles that prompted manufacturers and contract partners to reassess sourcing geographies and inventory buffers. In response, several stakeholders accelerated nearshoring initiatives and diversified supplier networks to mitigate exposure to tariff-related disruptions.

Beyond procurement, tariffs influenced capital expenditure decisions for new manufacturing capacity, particularly for complex modalities that require specialized clean-room facilities and cold-chain infrastructure. Firms contemplating new plants weighed increased import duties on equipment and spare parts against long-term strategic imperatives for regional supply security. Moreover, higher landed costs for imported materials exerted pressure on pricing negotiations and distributor agreements, which in turn affected hospital and specialty clinic budgets for oncology therapeutics. These pressures reinforced the need for transparent cost-of-goods analyses and collaborative contracting mechanisms between manufacturers and payers.

Finally, tariffs intensified the focus on regulatory and customs harmonization to reduce administrative delays that compound the financial impact of trade measures. Stakeholders increasingly sought engagement with policymakers and industry associations to clarify tariff classifications for biologic and advanced therapy components, and to advocate for exemptions where national health priorities justified rapid access. As a consequence, companies that proactively adapted procurement strategies, reinforced regional manufacturing footprints, and engaged constructively with policymakers were better positioned to preserve supply continuity and protect patient access amid the changing trade environment.

Comprehensive segmentation analysis revealing how therapy modality, mechanism, care setting, administration route, and patient demographics define clinical and commercial strategies

Segmentation insights reveal differentiated opportunities and operational demands across therapy types, mechanisms, lines of therapy, end users, routes of administration, and patient age cohorts. Therapeutic modality choices span biologic options such as antibody drug conjugates, fusion proteins, and monoclonal antibodies; cell therapies including CAR T approaches and stem cell transplantation; gene therapies; and a range of small molecules where BCL-2 inhibitors, DNA methyltransferase inhibitors, and tyrosine kinase inhibitors, with further subdivision into FLT3 and KIT targeted agents, play a central role. These modality distinctions carry distinct implications for clinical trial design, manufacturing complexity, and post-approval evidence generation.

Mechanism-focused segmentation underscores how BCL-2 inhibition, epigenetic modulation via DNA methyltransferase inhibitors, histone deacetylase modulation, immunomodulatory agents, and tyrosine kinase inhibition differentially influence combination strategies and resistance management. In terms of line of therapy, first-line paradigms prioritize durability and tolerability in newly diagnosed populations, second-line treatments emphasize salvage efficacy and safety, and third-line and beyond options concentrate on overcoming acquired resistance and managing cumulative toxicity. End-user segmentation highlights that hospital pharmacies must coordinate inpatient administration and cold-chain storage for complex biologics, retail pharmacies navigate outpatient dispensing of oral regimens, and specialty clinics deliver advanced cellular therapies under highly controlled conditions.

Route-of-administration segmentation differentiates intravenous therapies that demand infusion infrastructure and monitoring from oral agents that enable at-home dosing but require adherence support, while subcutaneous options can reduce infusion burdens yet require patient education and administration training. Patient age segmentation shows that adult cohorts constitute the bulk of treatment decisions with geriatric populations often necessitating adapted dosing and comorbidity management, whereas pediatric cases require bespoke safety and developmental considerations. Integrating these segmentation lenses enables stakeholders to prioritize clinical development pathways, align manufacturing and distribution investments, and design differentiated market access approaches tailored to modality, mechanism, care setting, and patient demographics.

An in-depth regional perspective highlighting differentiated adoption drivers, regulatory expectations, and operational priorities across major global markets

Regional insights underscore divergent drivers of adoption, regulatory expectations, and operational priorities across the Americas, Europe Middle East and Africa, and Asia-Pacific regions, each presenting unique implications for clinical development and commercialization. In the Americas, fragmented payer landscapes and advanced reimbursement mechanisms coexist with robust clinical trial networks and established oncology centers, creating an environment where evidence generation and value demonstration are critical to premium access and uptake. Conversely, Europe Middle East and Africa encompasses a mix of centralized regulatory frameworks and variable reimbursement thresholds, which heightens the importance of health technology assessment alignment and regional pricing strategies.

Asia-Pacific presents accelerated adoption potential driven by large patient populations, growing diagnostic capabilities, and expanding manufacturing capacity, yet it also features diverse regulatory regimes and cost-sensitivity that necessitate regionalized clinical development plans and flexible commercial models. Across all regions, logistical considerations such as cold-chain robustness, local manufacturing partnerships, and expedited regulatory engagement materially affect launch sequencing and access timelines. Therefore, a regionally nuanced approach that balances centralized global coordination with local execution capacity will optimize patient reach and commercial sustainability.

Strategic company behaviors and competitive alignments that combine scientific differentiation with manufacturing scale and payer-focused evidence generation

Leading companies in the AML therapeutics ecosystem are pursuing strategies that blend deep scientific differentiation with pragmatic commercial planning. Large pharmaceutical organizations are leveraging established commercial infrastructure and global development expertise to accelerate late-stage programs and to secure payer conversations early. Mid-sized biotechs and specialized cell therapy firms focus on nimble innovation, targeting molecularly defined subpopulations and pursuing strategic collaborations to fill capability gaps in manufacturing and global access. Across the board, companies are increasingly forming alliances that combine proprietary platforms with complementary assets to de-risk clinical pathways and to scale complex manufacturing processes.

Manufacturing partners and contract development organizations are scaling capabilities for advanced modalities, investing in single-use technologies, closed-system cell processing, and decentralized fill-finish solutions to support faster patient access. At the same time, market entrants emphasize differentiated clinical trial designs that incorporate biomarker-driven enrollment and adaptive endpoints to generate compelling evidence for regulators and payers. Commercial playbooks reflect a shift toward value-based pricing discussions, outcomes tracking, and integrated service offerings that include diagnostics and patient support. Firms that integrate clinical innovation with supply-chain robustness and payer-aligned evidence generation maintain a competitive advantage in translating scientific promise into sustainable patient access.

Actionable strategic recommendations that align clinical development, manufacturing resilience, and payer engagement to accelerate access and commercial success

Industry leaders should pursue a set of pragmatic, high-impact actions that align R&D priorities with commercialization realities while safeguarding supply continuity and payer relationships. First, prioritize biomarker-driven clinical pathways and adaptive trial designs that de-risk late-stage development and enhance the probability of regulatory approval and reimbursement. Second, accelerate diversification of supplier networks and consider regional manufacturing investments to reduce exposure to trade-related disruptions and to shorten time-to-patient. Third, embed health economics and outcomes research early in development plans to generate the real-world evidence required for value-based contracting and to support differentiated pricing conversations.

Moreover, cultivate cross-sector partnerships that combine discovery platforms with manufacturing and distribution expertise to accelerate scale-up of complex modalities. Invest in digital tools for remote patient monitoring and adherence support, particularly for oral and subcutaneous therapies, to demonstrate real-world effectiveness and to support outcomes-based agreements. Finally, engage proactively with policymakers and payer stakeholders to clarify reimbursement pathways for one-time and high-cost therapies, and to advocate for regulatory harmonization that reduces administrative barriers to timely access. Collectively, these actions will strengthen resilience, expedite access, and align commercial expectations with clinical realities.

A transparent and rigorous mixed-methods research approach combining primary expert interviews, secondary literature review, and evidence triangulation to ensure dependable insights

The research methodology employed a layered and reproducible approach combining both qualitative and quantitative techniques to ensure robustness and triangulation of findings. Primary research included structured interviews with clinicians, clinical trial investigators, payers, and industry executives to capture frontline perspectives on clinical practice, reimbursement dynamics, and operational constraints. Expert consultations informed scenario analyses around supply-chain disruptions and regulatory shifts, while investigator-initiated study reviews provided context for real-world treatment patterns and off-label usage.

Secondary research encompassed a comprehensive review of peer-reviewed literature, clinical trial registries, regulatory guidances, and company disclosures to construct an evidence base for mechanism-specific efficacy and safety profiles. Commercial intelligence was derived from product labeling, conference proceedings, and public tenders to assess accessibility considerations across care settings. Data synthesis applied qualitative coding, comparative framework analysis, and cross-validation against multiple independent sources to reduce bias and to enhance credibility. Throughout, methodological transparency was maintained by documenting data provenance and by subjecting key assumptions to sensitivity checks and expert validation.

A concise integrative synthesis emphasizing coordinated clinical, manufacturing, and commercial strategies required to realize durable patient impact

In conclusion, the AML therapeutics landscape is characterized by accelerated scientific innovation, shifting regulatory and payer expectations, and evolving operational complexities that together redefine pathways to patient access. Success requires integrated strategies that pair molecularly targeted clinical development with resilient manufacturing, payer-aligned evidence generation, and regionally tailored commercialization plans. Stakeholders that proactively address supply-chain vulnerabilities, adopt adaptive clinical designs, and engage payers early will be better equipped to translate therapeutic advances into sustainable clinical and commercial outcomes.

Looking ahead, the intersection of precision diagnostics, advanced biologics, and cell therapies presents substantial promise for improving patient outcomes, provided that industry actors coordinate across scientific, regulatory, and commercial domains. By aligning investments in capability building with strategic partnerships and by embedding health-economic thinking throughout development programs, organizations can navigate complexity and deliver meaningful value to patients and healthcare systems alike.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Emergence of FLT3 inhibitors in frontline and relapsed/refractory AML treatment landscape with improved survival outcomes
• 5.2. Expansion of menin inhibitors targeting MLL-rearranged and NPM1-mutant acute myeloid leukemia in clinical trials
• 5.3. Development of bispecific T-cell engagers against CD33 and CD123 antigens driving immunotherapy innovation in AML
• 5.4. Integration of MRD-guided therapy adjustments using next-generation sequencing to personalize AML treatment strategies
• 5.5. Approval and commercialization of oral BCL-2 inhibitor regimens offering chemo-free options for elderly AML patients
• 5.6. Investigation of CAR-T cell therapies targeting AML-specific antigens to overcome treatment resistance in relapsed cases
• 5.7. Adoption of targeted epigenetic modulators like IDH1/2 inhibitors shaping the therapeutic paradigm in AML management

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Acute Myeloid Leukemia Therapeutics Market, by Therapy Type

• 8.1. Biologic
  • 8.1.1. Antibody Drug Conjugates
  • 8.1.2. Fusion Proteins
  • 8.1.3. Monoclonal Antibodies
• 8.2. Cell Therapy
  • 8.2.1. CAR T Cell Therapy
  • 8.2.2. Stem Cell Transplantation
• 8.3. Gene Therapy
• 8.4. Small Molecule
  • 8.4.1. BCL-2 Inhibitors
  • 8.4.2. DNA Methyltransferase Inhibitors
  • 8.4.3. Tyrosine Kinase Inhibitors
    • 8.4.3.1. FLT3 Inhibitors
    • 8.4.3.2. KIT Inhibitors

9. Acute Myeloid Leukemia Therapeutics Market, by Mechanism Of Action

• 9.1. BCL-2 Inhibitors
• 9.2. DNA Methyltransferase Inhibitors
• 9.3. HDAC Inhibitors
• 9.4. Immunomodulatory Agents
• 9.5. Tyrosine Kinase Inhibitors

10. Acute Myeloid Leukemia Therapeutics Market, by Line Of Therapy

• 10.1. First Line
• 10.2. Second Line
• 10.3. Third Line And Beyond

11. Acute Myeloid Leukemia Therapeutics Market, by End User

• 11.1. Hospital Pharmacy
• 11.2. Retail Pharmacy
• 11.3. Specialty Clinic

12. Acute Myeloid Leukemia Therapeutics Market, by Route Of Administration

• 12.1. Intravenous
• 12.2. Oral
• 12.3. Subcutaneous

13. Acute Myeloid Leukemia Therapeutics Market, by Patient Age

• 13.1. Adult
• 13.2. Geriatric
• 13.3. Pediatric

14. Acute Myeloid Leukemia Therapeutics Market, by Region

• 14.1. Americas
  • 14.1.1. North America
  • 14.1.2. Latin America
• 14.2. Europe, Middle East & Africa
  • 14.2.1. Europe
  • 14.2.2. Middle East
  • 14.2.3. Africa
• 14.3. Asia-Pacific

15. Acute Myeloid Leukemia Therapeutics Market, by Group

• 15.1. ASEAN
• 15.2. GCC
• 15.3. European Union
• 15.4. BRICS
• 15.5. G7
• 15.6. NATO

16. Acute Myeloid Leukemia Therapeutics Market, by Country

• 16.1. United States
• 16.2. Canada
• 16.3. Mexico
• 16.4. Brazil
• 16.5. United Kingdom
• 16.6. Germany
• 16.7. France
• 16.8. Russia
• 16.9. Italy
• 16.10. Spain
• 16.11. China
• 16.12. India
• 16.13. Japan
• 16.14. Australia
• 16.15. South Korea

17. Competitive Landscape

• 17.1. Market Share Analysis, 2024
• 17.2. FPNV Positioning Matrix, 2024
• 17.3. Competitive Analysis
  • 17.3.1. AbbVie Inc.
  • 17.3.2. F. Hoffmann-La Roche Ltd
  • 17.3.3. Pfizer Inc.
  • 17.3.4. Jazz Pharmaceuticals plc
  • 17.3.5. Novartis AG
  • 17.3.6. Bristol Myers Squibb Company
  • 17.3.7. Astellas Pharma Inc.
  • 17.3.8. Agios Pharmaceuticals, Inc.
  • 17.3.9. Otsuka Pharmaceutical Co., Ltd.
  • 17.3.10. Daiichi Sankyo Company, Limited

LIST OF FIGURES

• FIGURE 1. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
• FIGURE 11. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2024 VS 2032 (%)
• FIGURE 13. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 15. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. NORTH AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. LATIN AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. EUROPE ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. MIDDLE EAST ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. ASIA-PACIFIC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. ASEAN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. GCC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. EUROPEAN UNION ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. BRICS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 28. G7 ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 29. NATO ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 30. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 31. ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 32. ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, BY REGION, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, BY REGION, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY FUSION PROTEINS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY FUSION PROTEINS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY FUSION PROTEINS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY FUSION PROTEINS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY FUSION PROTEINS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY FUSION PROTEINS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CAR T CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CAR T CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CAR T CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CAR T CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CAR T CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CAR T CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BCL-2 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BCL-2 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BCL-2 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BCL-2 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BCL-2 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BCL-2 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY FLT3 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY FLT3 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY FLT3 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY FLT3 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY FLT3 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY FLT3 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY KIT INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY KIT INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY KIT INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY KIT INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY KIT INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY KIT INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BCL-2 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BCL-2 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 103. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BCL-2 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BCL-2 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 105. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BCL-2 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BCL-2 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 107. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 109. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 110. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 111. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 112. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 113. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY HDAC INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 114. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY HDAC INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 115. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY HDAC INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 116. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY HDAC INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 117. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY HDAC INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 118. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY HDAC INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 119. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORY AGENTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 120. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORY AGENTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 121. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORY AGENTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 122. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORY AGENTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 123. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORY AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 124. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORY AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 125. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 126. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 127. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 128. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 129. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 130. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 131. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
• TABLE 132. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
• TABLE 133. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 134. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 135. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 136. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 137. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 138. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 139. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 140. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 141. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 142. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 143. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 144. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 145. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THIRD LINE AND BEYOND, BY REGION, 2018-2024 (USD MILLION)
• TABLE 146. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THIRD LINE AND BEYOND, BY REGION, 2025-2032 (USD MILLION)
• TABLE 147. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THIRD LINE AND BEYOND, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 148. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THIRD LINE AND BEYOND, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 149. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THIRD LINE AND BEYOND, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 150. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THIRD LINE AND BEYOND, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 151. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 152. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 153. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 154. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 155. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 156. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 157. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 158. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 159. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 160. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 161. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 162. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 163. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 164. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 165. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2024 (USD MILLION)
• TABLE 166. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2025-2032 (USD MILLION)
• TABLE 167. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINIC, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 168. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINIC, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 169. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINIC, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 170. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINIC, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 171. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 172. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 173. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 174. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 175. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 176. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 177. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 178. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 179. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 180. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 181. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 182. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 183. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 184. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 185. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 186. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 187. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 188. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 189. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 190. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 191. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
• TABLE 192. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2025-2032 (USD MILLION)
• TABLE 193. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 194. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 195. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 196. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 197. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 198. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 199. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
• TABLE 200. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2032 (USD MILLION)
• TABLE 201. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 202. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 203. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 204. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 205. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
• TABLE 206. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
• TABLE 207. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 208. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 209. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 210. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 211. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 212. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 213. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 214. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 215. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
• TABLE 216. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
• TABLE 217. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2018-2024 (USD MILLION)
• TABLE 218. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2025-2032 (USD MILLION)
• TABLE 219. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
• TABLE 220. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2025-2032 (USD MILLION)
• TABLE 221. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE, 2018-2024 (USD MILLION)
• TABLE 222. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE, 2025-2032 (USD MILLION)
• TABLE 223. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2024 (USD MILLION)
• TABLE 224. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2025-2032 (USD MILLION)
• TABLE 225. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
• TABLE 226. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
• TABLE 227. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
• TABLE 228. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
• TABLE 229. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 230. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 231. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 232. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 233. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
• TABLE 234. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2025-2032 (USD MILLION)
• TABLE 235. NORTH AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 236. NORTH AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 237. NORTH AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
• TABLE 238. NORTH AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
• TABLE 239. NORTH AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2018-2024 (USD MILLION)
• TABLE 240. NORTH AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2025-2032 (USD MILLION)
• TABLE 241. NORTH AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
• TABLE 242. NORTH AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2025-2032 (USD MILLION)
• TABLE 243. NORTH AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE, 2018-2024 (USD MILLION)
• TABLE 244. NORTH AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE, 2025-2032 (USD MILLION)
• TABLE 245. NORTH AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2024 (USD MILLION)
• TABLE 246. NORTH AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2025-2032 (USD MILLION)
• TABLE 247. NORTH AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
• TABLE 248. NORTH AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
• TABLE 249. NORTH AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
• TABLE 250. NORTH AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
• TABLE 251. NORTH AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 252. NORTH AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 253. NORTH AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 254. NORTH AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 255. NORTH AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
• TABLE 256. NORTH AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2025-2032 (USD MILLION)
• TABLE 257. LATIN AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 258. LATIN AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 259. LATIN AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
• TABLE 260. LATIN AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
• TABLE 261. LATIN AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2018-2024 (USD MILLION)
• TABLE 262. LATIN AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2025-2032 (USD MILLION)
• TABLE 263. LATIN AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
• TABLE 264. LATIN AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2025-2032 (USD MILLION)
• TABLE 265. LATIN AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE, 2018-2024 (USD MILLION)
• TABLE 266. LATIN AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE, 2025-2032 (USD MILLION)
• TABLE 267. LATIN AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2024 (USD MILLION)
• TABLE 268. LATIN AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2025-2032 (USD MILLION)
• TABLE 269. LATIN AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
• TABLE 270. LATIN AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
• TABLE 271. LATIN AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
• TABLE 272. LATIN AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
• TABLE 273. LATIN AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 274. LATIN AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 275. LATIN AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET